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Abstract: It was hypothesized that strontium (Sr)-dopedβ-tricalcium phosphate (TCP)-based scaffolds
have a positive effect on the regeneration of large bone defects (LBD). Readouts in our mice models
were nuclear factor-kappa beta (NF-κB) activity and vascular endothelial growth factor receptor-2
(VEGFR-2) promoter activity during the healing process. A 2-mm critical-size femoral fracture was
performed in transgenic NF-κB- and VEGFR-2-luciferase reporter mice. The fracture was filled with a
3D-printed β-TCP scaffold with or without Sr. A bioluminescence in-vivo imaging system was used
to sequentially investigate NF-κB and VEGFR-2 expression for two months. After sacrifice, soft and
osseous tissue formation in the fracture sites was histologically examined. NF-κB activity increased
in the β-TCP + Sr group in the latter stage (day 40–60). VEGFR-2 activity increased in the + Sr group
from days 0–15 but decreased and showed significantly less activity than the β-TCP and non-scaffold
groups from days 40–60. The new bone formation and soft tissue formation in the + Sr group were
significantly higher than in the β-TCP group, whereas the percentage of osseous tissue formation in
the β-TCP group was significantly higher than in the β-TCP + Sr group. We analyzed longitudinal
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VEGFR-2 promoter activity and NF-κB activity profiles, as respective agents of angiogenesis and
inflammation, during LBD healing. The extended inflammation phase and eventually more rapid
resorption of scaffold caused by the addition of strontium accelerates temporary bridging of the
fracture gaps. This finding has the potential to inform an improved treatment strategy for patients
who suffer from osteoporosis.
Keywords: large bone defects; β-tricalcium phosphate; strontium; NF-κB; VEGFR-2; bioluminescence
1. Introduction
Bone possesses a high endogenous capacity for repair and regeneration. Nevertheless, delayed
bone union and pseudarthrosis threaten the healing of large bone defects caused by tumor resection or
trauma. This limited capacity for bone regeneration can often be observed in patients with oxidative
stress-related diseases such as chronic inflammatory disease, type 2 diabetes mellitus, osteoporosis,
alcohol abuse, or heavy smoking [1,2].
Early-phase fracture healing requires hematoma formation, which provides a static base for migrating
inflammatory cells. The timely expiration of inflammation and early onset of revascularization periods are
critical for soft tissue and callus formation. In contrast, a prolonged inflammation phase and circulatory
impairment, separately or together, disturb the regular healing process [3,4]. Nuclear factor-kappa beta
(NF-κB), an inducer of numerous proinflammatory cytokines and chemokines, is reportedly a key indicator
in inflammation [5]. Impaired fracture healing is also associated with inadequate revascularization.
Vascular endothelial growth factor (VEGF) is critical in neoangiogenesis at the fracture site. One previous
study in animals has shown that blocking the VEGF receptors inhibits vascular in-growth, consequently
delaying or disrupting the regenerative process, whereas sufficient VEGF promotes fracture healing [6].
In particular, VEGFR-2 is reported to be a good indicator during the bone-healing process [7]. However,
there has been little discussion of the in-vivo longitudinal behavior of these inflammation and angiogenesis
markers during the fracture-healing process. Bioluminescence in vivo imaging systems can provide
real-time analysis of the various genes in order to address this gap [8,9].
Although the gold standard bone-grafting material is still an autologous graft, the attendant
harvesting of bone material constitutes a secondary surgery. Common materials currently being studied
for their potential as synthetic bone substitutes are collagen, hydroxyapatite (HA), calcium phosphate
scaffolds (CaPs), calcium phosphate-types of cement, and glass ceramics [10,11]. Among these,
β-tricalcium phosphate (TCP) is one of the most essential and most extensively investigated degradable
scaffolds used in the repair of bony defects [12–18]. Recent studies have harnessed the biodegradation
mechanisms, resorption, and fast bony adaption behavior in vivo of β-TCP scaffolds [19,20]. Many
reports have focused on the effect of single–ion substitutions, such as by strontium (Sr), in the β-TCP.
Strontium is well-known to enhance bone regeneration. Since the chemical properties of Sr and Ca
are very similar, the Sr can be incorporated into the bone structure, identical to Ca, in the mineral
phase [21]. Experimental and clinical studies refer to some beneficial effects of strontium ranelate in the
turnover of abnormal (and, in particular, of osteoporotic) bone, including increased osteogenesis and
bone formation, as well as reduced fracture incidence, even when administered systemically by oral
application [22,23]. Nevertheless, the oral application of strontium ranelate increases the risk of deep
venous thromboembolism due to systemic distribution and, therefore, should be avoided in patients
with the increased risk of stroke and ischemic cardiac disease [24]. The exact mechanism behind the
action of strontium still needs to be elucidated [25,26].
Therefore, we hypothesized that (a) the longitudinal analysis of inflammation and angiogenesis
during the bone-healing process in transgenic mice would be a beneficial alternative to endpoint-fracture
models, as it would reduce the number of animals involved, (b) the novel calcium phosphate-based
scaffold would enhance the healing process in critical-size bone defects, and c) the introduction of Sr
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into this scaffold would elevate bone formation and accelerate gap-bridging in our critical-size bone
fracture model. The aim of this study was to investigate the potential effects of novel β-TCP scaffolds
(with or without Sr) on bone formation in critical-size femur defects in mice and to longitudinally
evaluate inflammation and angiogenesis during the healing process with transgenic NF-κB- and
VEGFR-2-luciferase reporter mice.
2. Results
2.1. Longitudinal Monitoring of NF-κB Activity
NF-κB promoter activity in the fracture area was measured as a luminescence signal and detected on
a Xenogen imaging system. The longitudinal data (Figure 1) reveal increased NF-κB activity in all groups
up to the tenth day (with fold changes of 1.67 ± 0.22 in the control group and 1.68 ± 0.17 and 1.77 ± 0.19
in the β-TCP and β-TCP + Sr groups, respectively). NF-κB promoter activity decreases continuously in
the control group (1.47 ± 0.04 at day 20, 1.66 ± 0.13 at day 30, 1.36 ± 0.13 at day 40, 1.55 ± 0.11 at day 50,
and 1.50 ± 0.10 at day 60; n = 4). In the group with β-TCP scaffolds, NF-κB promoter activity exhibits its
highest peak at day 20 (1.78± 0.27) and decreases continuously down to the level of the control group (1.67
± 0.12 at day 30, 1.41± 0.17 at day 40, 1.47± 0.10 at day 50, and 1.42± 0.08 at day 60; n = 5). In contrast, the
+ Sr group shows the least promoter activity at day 20 (1.50 ± 0.26), though it increases again significantly
in the latter stage of healing, peaking after 40 days (1.77 ± 0.11 at day 30, 2.25 ± 0.13 at day 40, 2.00 ± 0.16
at day 50, and 2.02 ± 0.19 at day 60; n ≥ 6; p ≤ 0.05).
2.2. Longitudinal Monitoring of VEGFR-2 Activity
VEGFR-2 promoter activity in the fracture area correlates with measured luminescence signals
(appearing as average radiance) in the region of interest (ROI), as detected on a Xenogen imaging System.
The longitudinal data (Figure 2) reveal an increase in VEGFR-2 activity in all groups up to the
tenth day (3.73 ± 0.25 in the control group and 3.40 ± 0.59 and 3.76 ± 0.55 in the β-TCP and β-TCP + Sr
groups, respectively). VEGFR-2 promoter activity decreases both in the control and β-TCP groups at
day 15 (2.07 ± 0.13 and 2.35 ± 0.22, respectively) but steadily increases in the latter phase of the fracture
healing period (3.55 ± 0.31 at day 20, 3.56 ± 0.11 at day 30, 4.15 ± 0.63 at day 40, 2.95 ± 0.19 at day 50,
and 2.89 ±0.27 at day 60 in the control group; n = 4, and 3.19 ± 0.61 at day 20, 4.05 ± 0.52 at day 30,
3.31 ± 0.52 at day 40, 4.12 ± 0.11 at day 50, and 3.47 ± 0.65 at day 60 in the β-TCP group; n = 4). The +
Sr group shows the highest peak in promoter activity at day 15 (4.50 ± 0.66), but unlike in the other
groups, promoter activity in the + Sr group decreases continuously and remains stably below the level
of the β-TCP group in the second half of the healing period (2.89 ± 0.23 at day 20, 2.80 ± 0.35 at day 30,
2.91 ± 0.54 at day 40, 2.08 ± 0.31 at day 50, and 1.87 ± 0.35 at day 60; n = 4; p ≤ 0.05).
2.3. Histological Analysis of Tissue Formation
Our histological examination revealed that osseous tissue had formed after two months but only
where scaffolds were employed. In the control group, with no scaffolds, the entire defective area was
filled with soft, connective tissue (Figure 3a). Our µCT analysis verified the lack of bony tissue between
bone gaps in the control group, whereas the channels had been filled in or replaced with bony tissue in
other groups (Figure 3b).









Figure 1. Longitudinal tracking of nuclear factor-kappa beta (NF-kB) activity during fracture healing
in transgenic mice. NF-κB promoter activity in the fracture area was measured as a luminescence
signal and appears as average radiance in the region of interest (ROI), as detected on a Xenogen
imaging system. Sr increased inflammation by means of NF-κB activity in the late healing stage.
The non-scaffold group is a nonunion group (n ≥ 4; p ≤ 0.05). βTCP: β-tricalcium phosphate, p value is
given as p ≤ 0.05. Asterisks indicate statistical differences within the groups.





Figure 2. Longitudinal tracking of vascular endothelial growth factor receptor-2 (VEGFR-2) activity
during fracture healing in transgenic mice. VEGFR-2 promoter activity in the fracture area was
measured as a luminescence signal and appears as the average radiance in the region of interest (ROI),
as detected on a Xenogen imaging system. We observed the first peaks of luciferase activity on day 10
(in the early angiogenesis period) in all groups. While the level of VEGFR-2 activity increases in the
Sr-doped β-TCP (β-TCP + Sr) group on day 15, luciferase activity starts to decrease in this group and
eventually shows significantly less activity here than in the other two groups in the second half (n ≥ 4;
p value is given as p ≤ 0.05. Asterisks indicate statistical differences within the groups).











Figure 3. Histological analysis of callus formation. In both the β-TCP and β-TCP + Sr groups, the
connections between newly formed tissue within the scaffolds’ integrated canals was clearly visible.
In the non-scaffold control group, a connective tissue formation was observed (a,b). (b) Micro-CT
analysis shows coronal (i) and transversal (ii) sections of a scaffold after two months. The brown
cylinder marked with an asterisk represents the soft tissue in fracture gaps in the control group. The
channels in both β-TCP and β-TCP + Sr groups are filled with or replaced by soft and bony tissue
(gray). (c) The y-axis shows the percentages of newly formed (gray) and bony (red) tissues in relation
to the scaffold area. Our histological analysis showed that much more tissue had been built in the
β-TCP + Sr group than in the β-TCP group. The y-axis shows the percentage of osseous tissue (red) in
relation to the scaffold area (gray). Bone formation in the β-TCP + Sr group was significantly higher
than in the β-TCP group (red asterisk). (d) In contrast, the percentage of osseous tissue among all
newly formed tissue was much higher in the β-TCP scaffold group than in the β-TCP + Sr scaffold
group (n ≥ 4; p ≤ 0.05. Red asterisks indicate statistical differences of relative bony tissue formation and
black asterisks indicate statistical differences of relative tissue replacement within the groups).
In both the β-TCP and β-TCP + Sr groups, the newly formed tissue within the scaffold area
was visibly connected to the ends of the fracture. The + Sr group showed significantly higher tissue
regeneration (61.93% ± 3.04%) than the β-TCP group (26.41% ± 1.31%) (Figure 3c).
We also determined the percentage of ossified tissue and amount of ossified tissue in proportion
to all the newly formed tissue. The percentage of bone formation in the β-TCP + Sr group (10.13% ±
1.4%) was significantly higher than in the β-TCP group (6.53% ± 0.99%) (red column). The relative
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amount of ossified tissue to all newly formed tissue was higher in the β-TCP group than in the β-TCP
+ Sr group. In the β-TCP group, 27.92% ± 3.45% of all tissue was ossified, whereas only 16.80% ± 2.30%
of the tissue in the β-TCP + Sr group could be identified as ossified (Figure 3d).
2.4. Relative Protein Expression of Osterix (Osx) in Scaffolds
To verify the examined Osx protein expression data in newly formed tissues in the scaffolds, we
performed an immunohistochemistry analysis (Figure 4a) and calculated the ratio of Osx-positive cells
to total cells (Figure 4b). The percentage of Osx-positive cells in the β-TCP group (22.60% ± 2.88%)













β β ≥ ≤
Figure 4. Relative protein expression of Osterix in the scaffold. (a) The images represent sections that
have been immunohistochemically stained against Osterix (Osx) in the vicinity of newly formed tissue
in the scaffold (red square) in both the β-TCP (left) and β-TCP + Sr (right) groups. Green arrows
indicate Osx-positive cells shown up by red staining. (b) The ratio of Osx-positive to total cells in the
β-TCP group was significantly higher than in the β-TCP + Sr group (n ≥ 3; p value is given as p ≤ 0.05.
Asterisks indicate statistical differences within the groups).
2.5. Quantification of Bone-Marker Levels in Serum
Using a Luminex® technology, the protein levels of fibroblast growth factor 23 (FGF-23), osteocalcin
(OC), osteoprotegerin (OPG), Dickkopf-related protein 1 (DKK), insulin, and leptin were quantified in
the animals both before and two months after the operation.
The results showed a significant reduction of osteocalcin levels in the β-TCP group (201,640 ±
20,183 pg/mL vs. 114,419 ± 15,713 pg/mL; n = 4; p ≤ 0.05) and a significant increase in osteoprotegerin
levels in the β-TCP + Sr group (3736 ± 200.5 pg/mL vs. 5232 ± 338.9 pg/mL; n = 4; p ≤ 0.05) during the
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healing process. No significant differences in the protein levels of FGF, DKK, insulin, and leptin were to be







Figure 5. Quantification of growth factors in the serum. Levels of fibroblast growth factor (FGF),
osteocalcin (OC), osteoprotegerin (OPG), Dickkopf-related protein 1 (DKK), insulin, and leptin were
quantified using the Luminex system in the serum. These markers were compared among all three
(control, β-TCP, and β-TCP + Sr) groups both before, as well as two months after, surgery (n = 4).
* p ≤ 0.05 indicates significance.
3. Discussion
3.1. Use of Transgenic Mice
The use of animal models has made it possible to study fracture healing from various perspectives,
such as histology, biochemistry, and biomechanics, and has hence been an essential tool for the
development of improved therapies to bone regeneration [27].
Mice fracture models are economical and widely used to analyze the various molecular mechanisms
of bone regeneration and the healing process. The longitudinal in-vivo techniques allow a further
reduction of the number of animals and arrange to get the interim data about the animal. Most
published data are based on µCT, histochemistry, and immunohistochemistry. µCT is the gold standard
method for the evaluation of mineralized tissue. Using of µCT by analysis of fractures, which are
stabilized by external fixators, are an elaborate procedure to the presence of screws and metal parts
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used to stabilize the fracture [28]. Additionally, the mineralization of a fracture is proceeded by
assuming soft fiber and cartilage tissue of the callus. µCT analysis cannot deliver precise data about
the process of the initiate inflammation period or vascularization and soft callus formation in the early
phase of fracture healing [29,30]. The local inflammatory process could be illustrated, so far, mostly in
two-week intervals after euthanizing the animal using histological and immunohistological staining.
Haffner-Luntzer et al. established an MRI-compatible osteosynthesis device to evaluate the callus
formation in mice femurs in vivo [31]. The MRI technique is not a sufficient longitudinal method
for the investigation of a critical-size fracture due to the application of a metallic part of the fixator.
Bioluminescence in-vivo imaging systems allow real-time analysis of various genes [8,9] and is used in
our study.
3.2. Longitudinal NF-κB Activity during Fracture Healing
The present study, which investigates the longitudinal course of NF-κB activity during the
fracture-healing process, is the first of its kind. Our results, which show increased NF-κB activity
in the early phase of fracture healing in all groups, point to the intervent, intervened inflammatory
response, which we know is associated with bone defects. Three weeks after fracture, NF-κB activity
in the β-TCP group is tendentially higher than it is in the β-TCP group, with strontium scaffolds (+ Sr),
and this would indicate that strontium has anti-inflammatory effects during the early phase of fracture
healing. Previous studies have reported that strontium can have immunomodulatory properties [25].
Lourenco et al. found that fewer inflammatory cells were recruited to a strontium implant site than to
that of a sham operation in rodents [25]. Similar to our study, they obtained their results within around
two weeks of implantation. However, the specific amount of strontium in the scaffolds can affect the
release of Sr2+ [32].
On the other hand, NF-κB activity tended to decrease in the latter phase of fracture healing in
both the non-scaffolded as well as the β-TCP-scaffolded group, but in the strontium (+ Sr) group,
by contrast, NF-κB activity shows a significant increase beginning around day 40 after the fracture.
The immunomodulatory properties of Sr is discussed in some studies [25,33], but as far as we know,
such an anti-inflammatory effect of strontium has never been reported in a study featuring longitudinal
monitoring. Acute inflammation is a crucial biological process for tissue homeostasis in the early
phase of fracture healing. Successful clearance of inflammatory stimulation due to anti-inflammatory
and reparative cytokines generally resolves the inflammatory situation and re-establishes tissue
homeostasis [34–37]. Conversely, persistent proinflammation can result in chronic inflammation
and impaired fracture healing [38–40]. Diseases characterized by chronic inflammation (such as
osteoarthritis or rheumatoid arthritis) increase the risk of nonunion after fracture [41,42]. Our study
indicates there is a possibility that strontium may lead to impaired fracture healing in a chronic
inflammation environment.
3.3. Longitudinal VEGFR-2 Activity during Fracture Healing
In the present study, VEGFR-2 activity increased immediately after the fracture in all groups, which
suggests neovascularization in the bone defect in the early phase of bone healing. Revascularization
after the injury acts as a critical process for soft callus formation during regeneration [43]. Two weeks
after the fracture, activity decreased in both the β-TCP and non-scaffolded groups. This stands in
contrast with an increase in VEGFR-2 activity in the strontium (+ Sr) group two weeks after the fracture,
which suggests that strontium may promote vascular formation and tissue repair by activating VEGF
in the reparative phase of fracture healing. Although VEGFR-2 activity in the strontium group declined
in the latter stage, strontium may have a positive effect on tissue formation toward fracture healing in
the long run.
On the other hand, VEGFR-2 activity exhibited sequentially higher values in the β-TCP group
than in the non-scaffolded group. The interdependency of the respective time cascades of inflammation,
angiogenesis, and tissue regeneration is described by Schmidt-Bleek et al. [3]. Our current longitudinal
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results indicate the β-TCP scaffold had a positive effect on fracture healing because of the associated
continuous activation of VEGFR-2.
3.4. Bone and Tissue Regeneration
Our histopathological findings, which we obtained two months after the fracture, reflect
significantly higher relative tissue formations in the β-TCP + Sr group than in the non-strontium
β-TCP group.
VEGF positively influences the soft callus formation through neovascularization during the
fracture-healing process [44,45]. Thus, a further increase in VEGFR-2 activity two weeks after the
fracture might have led to higher relative tissue formation in the strontium (+ Sr) group, even two
months after the fracture. The level of OPG in the serum in the strontium group was likewise
significantly higher two months after surgery than prior to it, and serum levels of the OC remained
constant in the + Sr group after surgery, though they decreased significantly in the other groups. On the
other hand, our histopathology showed a significant decrease in the bone percentage of new tissue in the
β-TCP + Sr group compared with the non-strontium β-TCP group. Clinically, diseases associated with
chronic inflammation—including alcoholism, (morbid) obesity, osteoarthritis, rheumatoid arthritis,
and type II diabetes—increase the risk of nonunion [41,42]. Our present findings therefore suggest
that chronic inflammation associated with NF-κB activation in the latter phase of fracture healing can
disturb bone repair.
The short initial inflammatory phase and higher percentage of bony tissue relative to the + Sr
group suggests that our β-TCP group-type characteristics have a potential beneficial application in
treating critical-size fractures.
Nevertheless, the + Sr group exhibited greater tissue formation (albeit with a lower percentage of
bone), and these soft-and-bony tissue bridges filled the fracture gaps faster than was the case in the
β-TCP group. This effect may prove advantageous for fracture healing in patients who exhibit lowered
bone stability, such as those with osteoporosis.
Osterix (Osx) is an essential transcription factor for osteoblast differentiation; bone cannot form
without it. Takebe et al. was able to observe Osx-positive cells on the surface of a newly formed bone
matrix seven days after the fracture [46]. We saw very few Osx-positive cells, particularly in the + Sr
and non-scaffold groups. (Non-scaffold group data are not shown.) This may be attributable to the
fact that we analyzed Osx expression in the latter phase of fracture healing. The effect of Sr on Osx
expression is not sufficiently understood, and the existing data on Osx expression during Sr treatment
is controversial. Peng et al. found no significant changes in Osx gene expression in either their Sr or
control groups [47]. Liu et al., on the other hand, reported a dose-dependent increase in Osx-mRNA in
defective bone tissues implanted with 0%, 5%, or 10% Sr-CaS for eight weeks [48].
3.5. Feasible Size of Femur Defect in Mice
For the present study, we used a 3D-printed scaffold with a diameter of 2 mm and a height of
1.7 mm for a 2-mm bone defect in mice femur diaphyses. Accordingly, no sufficient bone or soft
tissues were obtained in the fracture gap without scaffolds. Additionally, previous studies have found
substantial bone formation in scaffolds inserted into a 2.3-mm bone defect in mice femurs [49,50]. Our
critical-size femur defect models in mice would therefore be useful for further studies of the role of
other scaffolds in fracture healing.
3.6. Strontium-Doped β-TCP Scaffold
Strontium salts as strontium citrate, strontium chloride, or strontium ranelate have shown to
overcome the bone loss in the in-vivo and in-vitro experiments [51,52]. Strontium citrate and chloride
are supplements, and their effectiveness is not sufficiently investigated so far. Oral administration of
strontium ranelate for the treatment of osteoporosis was approved for a long time [53]. Nevertheless,
the oral application of strontium ranelate increases the risk of deep venous thromboembolism due to
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systemic distribution and, therefore, should be avoided in patients with an increased risk of stroke and
ischemic cardiac disease [24]. To explore the positive effects of strontium, many reports have focused
on the local application of Sr as single–ion substitutions in the scaffolds [54–57]. We used Sr-doped
β-TCP in this study. The scaffolds were provided with channels inside. A diameter of 100 µm or
more has been shown to support new bone formation [58–60]. The used diameter of 300 µm in this
study mimics the trabecular structure of bone. Despite macroscopically identical structures produced
by the same molds, there was microscopical differences between the β-TCP scaffold and β-TCP + Sr
scaffold due to the average pore diameter, porosity, and total pore surface. Barba et al. have shown that
pore clustering and architecture play a critical role in osteoinductivity of the scaffold. They observed
that the sintered and biomimetic frameworks showed different bone formation patterns [61]. In-vitro
studies have shown that the nanostructure of osteoinductive materials influence the differentiation of
mesenchymal stem cells and upregulation of osteogenic genes without adding osteogenic factors [62].
The existing of fine differences in the microstructures of the used scaffolds in our study may have
influenced the new bone formation.
3.7. Limitations
The main limitation of this study is that the skin incision of subcutaneous tissue in longitudinal
monitoring can affect both NF-κB and VEGFR-2 activity. However, this method enables us to
sequentially evaluate both NF-κB and VEGFR-2 activities in the same mice and to reduce the number
of animal subjects.
A general limitation of longitudinal analyses of critical-size fracture healing, in which fractures
are stabilized by either an external or an internal fixator, is the degradation of µCT quality. The β-TCP
scaffold we used in the present study caused some degree of artifact in the µCT. The background signal
impairs the analysis of the new bone formations.
Our results represent the healing process we observed over an eight-week period, but the healing
process was not complete when we concluded our observations. An analysis of longer-term outcomes
would be needed to compare the biomechanical properties of replaced tissue, as well as the bony tissue
quality, in either group (with and without strontium).
4. Materials and Methods
4.1. Scaffold Manufacturing
The scaffolds used in this study were synthesized in accordance with Lindner et al. [12]. Strontium-
doped calcium phosphate suspensions with high solid contents were prepared using organic liquefier,
binder, and anti-foaming agents. The suspensions were cast into 3D-printed wax models for scaffold
production. The filled wax models were fired at 1200 ◦C for 3 h. Scaffolds manufactured by slip-casting
in 3D-printed wax molds were successfully adapted to fit into a critical-size defect mouse model
(Figures 6 and 7d,e). The scaffolds were downscaled to a diameter of 2 mm and a height of 1.7 mm.
The β-TCP scaffold used in this study had a porosity of 24.5 vol%. The total pore surface area was
0.3 m2/g, with an average pore diameter of 2.0 µm. The β-TCP + Sr scaffolds had a porosity of
22.1 vol%. The total pore surface was 0.4 m2/g, and the average pore diameter was 1.5 µm. The scaffolds
exhibited a compression strength of 9.4 ± 2.1 MPa. The solubility of strontium in PBS was 65 ng/mm2
after 21 days. We also characterized the cytocompatibility of both scaffolds [58]. In addition to the
micropores, having a macro-porosity of more than 100 µm is evidence to mimic the trabecular bone
infrastructure and guarantee the cell migration and vascularization in the scaffold [59]. Therefore, we
used three macro-canals to warrant the trabecular building and capillary formation.















Figure 7. Implantation of novelβ-tricalcium phosphate scaffolds in critical-size fractures. A longitudinal
incision along the femur was performed (a). Then the Mouse ExFix (RISystem) was positioned on
the femur. Subsequently, the bone was stabilized by an external fixator using four screws (b). Using
the two grooves in the saw guide, a defined fracture gap of 2 mm was created with a Gigli saw (c).
The wound was washed with Ringer’s solution, and the scaffold (d) was implanted into the fracture
gap (e). µCT evaluates the position of the scaffold and external fixator (f).
4.2. Transgenic Animals
For in-vivo imaging purposes, transgenic reporter mice have been genetically engineered with a
luciferase gene cloned to transcriptional promoters that are responsible for the expression of VEGFR-2
or NF-κB.
For this study, we used twelve luciferase transgenic mice of the strain (BALB/C-Tg (NF-κB-
RE-luc)-Xen and twelve luciferase transgenic mice of the strain FVB/N-Tg (Vegfr-2-luc)-Xen), all
between 19–21 weeks of age.
All mice were kept in suitable mouse cages and acclimated for one week prior to the start of the
study. Mice were exposed to a 12-h light-and-dark cycle via artificial illumination (light period: 7 a.m.
to 7 p.m.) and kept at a controlled room temperature of 22 ± 2 ◦C in specific pathogen-free conditions.
Food pellets and water were available ad libitum. Autoclaved wood chippings were used as bedding
material. All procedures were performed with the approval of the appropriate governmental institution
(Landesamt für Natur-, Umwelt- und Verbraucherschutz, LANUV NRW, Bonn, Germany, reference
number: AZ 84-02.04.2012.A029).
4.3. Critical-Size Fracture Model (Large Bone Defect)
Before surgery, the lower backsides of the mice were shaved and disinfected. Anesthesia was
induced with intraperitoneal administration of a mixture of xylazine (8 mg/kg animal weight) and
ketamine (100 mg/kg animal weight). After administration of the narcotic agent, surgical tolerance was
tested by toe pinch and whiskers’ reflexes to ensure deep anesthesia. Bepanthen eye cream was applied
to avoid desiccation, and the animals were placed on a warming mat for the duration of the surgery.
A longitudinal incision was performed along the femur. The fascia and muscles were removed to
expose the length of the femur (Figure 7a). Then a Mouse Ex-Fix was attached to a saw-guide fixator
positioned on the prepared femur in an anterolateral direction parallel to the longitudinal axis of the
bone. The bone was subsequently stabilized by an external fixator using four screws (RISystem, Davos,
Switzerland) [28].
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Using the two grooves in the saw guide (Figure 7b), a defined fracture gap of 2 mm was created
using a 0.22-mm Gigli saw (Figure 7c; RISystem, Davos, Switzerland) in the middle of the femur. The
wound was washed with ringer solution, and the scaffold was implanted into the fracture gap via
press-fitting (Figure 7d,e). One group received the osteotomy but no scaffold. We were also able to
use X-ray and micro-computed tomography (µCT) to monitor how well the scaffold position was
maintained (Figure 7f,g).
The muscular layer and fascia were sutured first; the skin was sutured later. After surgery, the
animals were closely watched until they awoke from anesthesia. They were exposed to infrared light
to stave off hypothermia. Additionally, a dose of buprenorphine (0.1 mg/kg body weight) was injected
subcutaneously to ensure proper analgesia. Buprenorphine application continued post-surgery twice a
day for 7 days.
In the first group, an external fixator was attached and an osteotomy performed without implanting
a scaffold. The second group consisted of animals that had been implanted with a β-TCP scaffold.
The third group contained animals implanted with a β-TCP + Sr scaffold.
4.4. In-Vivo Luminescent Imaging
The mice received an intraperitoneal injection of 200 µL of D-luciferin (150 mg/kg) 10 min before
imaging to allow time for D-luciferin distribution. Luciferase activity was visualized afterwards.
The D-luciferin solution (Synchem OHG, Felsberg/Altenburg, Germany) was prepared as described by
Fet et al. [60]. The mice were placed in the chamber (IVIS Lumina, Caliper Life Sciences, Hopkinton,
MA, USA) under continuous anesthesia (2.5% isoflurane and 2 L/min oxygen flow by inhalation).
Whole-body NF-κB or VEGFR-2 activity-related luminescence was then imaged on an in-vivo imaging
system. Bioluminescence measurements were taken before the surgical intervention and then after it
once a week [6]. Measurement parameters were set to 10 min integration time and the field of view to







Figure 8. Longitudinal monitoring of ongoing angiogenesis and inflammatory processes by detecting
bioluminescence signals in vivo. The expression levels of VEGFR-2 and the activity of NF-κB
(representing either angiogenesis or inflammation) were monitored noninvasively, in longitudinal
fashion, using the Xenogen imaging system (IVIS Lumina Imaging System 100) (Caliper Life Sciences,
Hopkinton, MA, USA). Luciferase activity was visualized after intraperitoneal injection of 200µL of
D-luciferin (150 mg/kg) (a). Mice were placed in the chamber (IVIS Lumina, Caliper Life Sciences,
Hopkinton, MA, USA) (b) under continuous anesthesia (2.5% isoflurane and 2 L/min oxygen flow by
inhalation (c) 10 min before imaging (to allow D-luciferin distribution). To quantify the luminescence,
elliptical regions of interest (ROIs) were placed on the right and left limb (ROI 1 and ROI 2) (d). At each
time point, ROI luminescence was measured as the average radiance (photons per second per square
centimeter per steradian: p/s/cm2/sr) for all animals. To reduce the false negative effect of the fixator
plate, signals from the second square ROI in the same volume as the fixator plate (ROI 3 and ROI 4)
were subtracted from both the right and left elliptical regions (d).
To quantify luminescence, elliptical regions of interest (ROI) were placed on the right and left limbs.
The ROIs were selected to encompass the majority of the respective variances in NF-κB or VEGFR-2
activity, as observed in the imaging dataset. At the time of each observation, ROI luminescence
was measured as the average radiance (in photons per second per square centimeter per steradian:
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p/s/cm2/sr) for all animals. To reduce any false negative effects from the fixator plate, we subtracted the
second square ROI in the same volume as the fixator plate from both the right and the left elliptical
ROIs (Figure 8d). Luminescence data for each animal and each point in time was normalized to
luminescence values from the contralateral side of the same animal.
4.5. Micro-CT Imaging
The mice were scanned in a small-animal dual-source µCT (TomoScope Duo, CT-Imaging,
Erlangen, Germany). They were anesthetized during imaging by an application of isoflurane (2%
isoflurane in air; flow rate: 1 L/min). The sources of the flat-panel µCT were operated at a voltage of
65 kV and a current of 0.5 mA. A 90-s, full-rotation scan acquired 720 projections at a resolution of
1032 × 1012 pixels [61].
Reconstructions were performed with voxel sizes of 35 µm using a Feldkamp-type algorithm. The
volumetric images were visualized and analyzed using the Imalytics Preclinical software [62].
4.6. Histological Staining
The femur samples were prepared and placed into methacarn solution for fixation lasting a total
of 24 h. Subsequently, the legs were decalcified in a 10% EDTA buffer for 21 days; then, they were
washed under running tap water and dehydrated in an ascending ethanol series (from 70% to 100%
ethanol). Afterwards, tissues were first placed in xylene and, then, in 56 ◦C preheated paraffin wax (for
paraffin infiltration). Tissues were then embedded in paraffin and left to solidify at room temperature
(RT). The paraffin block was cut into 4.5-µm-thick sagittal sections using a microtome. The sections
were left to dry and kept at RT to await further processing.
4.7. AZAN Staining
Approximately one out of every fifteen serial sections of femur were used for azan staining to
visualize the formation of both soft and hard tissue (Figure 9). Azan staining was carried out in
accordance with the standard protocols described by Mulisch and Welsch et al. [60,63]. Acocarmin
G and Anilinblau-Goldorange are used for a trichrome stain to mark different tissues histologically.
Azan stains muscle fibers and osseous tissues red and cartilage/bone matrix and fibrous tissues blue.
 
relative tissue formation %  =       ∙  100
relative bone formation %  =       ∙  100
Figure 9. Histological analysis of the fracture site. Micro-CT image of the femur after two months
(a). The red line represents the histological serial section of the femur (a). The critical-size defect was
visualized using azan staining. Regenerated tissue formation was stained in the channel holes of the
scaffold (b). The scaffolded area (white, c), tissue-free area (green, d), and bone formation (red, e) were
quantified and used to calculate the amounts of regenerated tissues and bone for each group after
two months.
The area around the scaffold, the tissue-free area, and the bone area were examined using a
microscopical approach (Keyence BZ-9000; Keyence, Osaka, Japan). To measure the area of newly
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formed tissue, the tissue-free area was subtracted from the total area of the scaffold (Figure 9). Relative
tissue formation and relative bone formation were determined by the following equations:
relative tissue formation (%) =
(
new tissue area
total sca f f old area
)
· 100 (1)
relative bone formation (%) =
(
new bone area
total sca f f old area
)
· 100 (2)
Average values were used for data presentation.
4.8. Immunohistochemical Staining Analysis
Routine immunohistochemical procedures were performed on various slides from each group.
The deparaffinized sections were soaked in 3% hydrogen peroxide (H2O2) in methanol at room
temperature for 15 min to inhibit endogenous peroxidase activity. The sections were then washed
3 times with Tris-buffered saline (TBS) and blocked with swine serum (Agilent DAKO, Santa Clara,
CA, USA, Cat# x0901; 1:20 in TBS). Afterwards, sections were incubated for 24 h at 4 ◦C with primary
antibodies against Osterix (Osx, Santa Cruz Biotechnology, Heidelberg, Germany; Cat# Sc22536-R;
1:250 in 1.5% BSA in TBS). The primary antibody was omitted in the negative control experiments.
After being washed for 3 × 5 min in TBS, the sections were incubated with biotinylated polyclonal
swine anti-rabbit immunoglobulins (Agilent DAKO, Santa Clara, CA, USA, Cat#E0353; 1:400) as
secondary antibodies for 30 min. The sections were then visualized with an AEC-Kit (Invitrogen
Corporation, Carlsbad, CA, USA) for 5 min. They were then counterstained with hematoxylin. Images
of the scaffold area were taken using a Keyence BZ-9000 microscope (Keyence, Osaka, Japan) with a
20× objective lens. The protein expression of Osx in the scaffold area was determined by the relative
value of positive-stained cells to total cells in the new tissue area in at least three different regions of
the same section as ascertained by two examiners who were blinded to the project. The mean of all
values per section was then calculated.
4.9. Quantification of Serum Protein Level
The concentrations of osteocalcin, osteoprotegerin, and fibroblast growth factor 23 (FGF-23) were
analyzed using a Luminex multiplex immunobead assay (Luminex Corp., Austin, TX, USA) based
on xMAP technology. The BioPlex kit (Bio-Rad Laboratories, Hercules, CA, USA) was performed
strictly as described in the manufacturer’s guidelines. Two-hundred microliters of whole blood was
collected from the retrobulbar area and left undisturbed to clot. Serum was separated by centrifugation
at 18,000× g for 1 min and then stored at −80 ◦C. The serum sample was diluted 1:4 with the serum
dilution included in the kit.
4.10. Statistical Methods
Prior to statistical analysis, residuals were tested for normal distribution with the Shapiro-Wilk
normality test and for variance homogeneity with the Bartlett’s test. If one of the aforementioned
tests were significant, the data were transformed, and residual normal distribution and variance
homogeneity were then re-evaluated. Intergroup differences were tested by one-way ANOVA
(except for the longitudinal data) or two-way ANOVA (repeated measure, using Greenhouse–Geisser
corrections), followed by Tukey’s post-hoc test. All statistical calculations and data presentations were
performed using GraphPad Prism, version 8.2.0 for Mac, GraphPad Software, San Diego, CA, USA,
www.graphpad.com. Data are given as a mean ± SEM. The level of significance was set at p ≤ 0.05 (*).
5. Conclusions
We present first-time profiles of the longitudinal activities of VEGFR-2 promoter and NF-κB—
respective agents of angiogenesis and inflammation—during critical-size bone-fracture healing.
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We found high percentages of osseous tissue in our β-TCP group, which could be the result of
high VEGFR-2-promoter activity in late-phase fracture healing.
The addition of strontium to calcium phosphate-based scaffolds influenced the inflammatory
response at various stages of the healing process and may have affected bone regeneration. An extended
inflammation phase caused by the addition of strontium accelerates tissue formation and, thus, the
bridging of fracture gaps, which may aid in the treatment of patients suffering from osteoporosis.
The precise impact of strontium-doped β-TCP in osteoporotic large-bone defects bears further study.
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